Takeda’s commitment to FIRAZYR

The patent for FIRAZYR® (icatibant injection) expired on July 15, 2019. After that date, generic versions of icatibant were made available. Brand name FIRAZYR continues to be available.

Takeda remains committed to you and your patients with hereditary angioedema (HAE)

At Takeda, our ongoing commitment to FIRAZYR includes the following:

  • Continued manufacturing and availability of FIRAZYR
  • Product support services through OnePath® for your eligible FIRAZYR patients

Contact the Takeda representative in your area with questions you may have about treatment with FIRAZYR.

Support through OnePath

OnePath® logo.

OnePath will continue to help support your enrolled patients by offering access to a dedicated Patient Support Manager (PSM).

Helping your patients who want to receive FIRAZYR

We are making resources available that offer information about how to help your patients who you decide should receive brand name FIRAZYR.

You can also contact the OnePath Patient Support Manager or Patient Access Manager in your area if you have questions about access to FIRAZYR.